You are in:Home/Publications/Effectiveness and Safety of Amaryl M in Every day Practice on Egyptian Patients Sanovy Aventis

Prof. Mostafa Soliman Abdel-Fattah El-Kady :: Publications:

Effectiveness and Safety of Amaryl M in Every day Practice on Egyptian Patients Sanovy Aventis
Authors: Not Available
Year: 2011
Keywords: Not Available
Journal: journal benha medical
Volume: Not Available
Issue: Not Available
Pages: Not Available
Publisher: Not Available
Local/International: International
Paper Link: Not Available
Full paper Not Available
Supplementary materials Not Available

Background : Type 2 diabetes mellitus (DM) is an incurable chronic disease needs long life treatment. So, the study of long - term safety and tolerability of oral hypoglycemic agents especially newer one is very important. The objective of this study was to compare safety and efficacy of vildagliptin with glimepiride in type 2 dia betic patients. Patients & Methods : 40 patients with type 2 DM were randomized to receive vildagliptin 50 mg or glimepiride 2 mg once daily as add - on therapy for 16 weeks. A vildagliptin group (23 patients) was received 50 mg vildagliptin once daily as add - on therapy, and glimepiride group (17 patients) was received 2 mg once daily as add - on therapy. The end point was the number of patients achieving HbA 1C (Glycated haemoglobin) 0.05 ). . Weight of patients in vildagliptin group were reduced while in glimepiride group there was increase in weight ( - 5.2 kg. vs. + 4.3kg, p ˂ 0.05). There was statistically significant difference in patient weights in both groups. Conclusion : Vildagliptin is effective as hypoglycemic agent, as glimepiride in controlling blood glucose level guided by reduction in fasting blood sugar and HbA1C. In addition to reduction in patient weight and is well tolerated

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus